Indications for SHINGRIX:
Prevention of herpes zoster (shingles) in adults ≥50yrs of age.
Limitations of Use:
Not for preventing primary varicella infection (chickenpox).
<50yrs: not recommended. Give by IM inj in deltoid region of upper arm. ≥50yrs: one 0.5mL dose at Month 0 followed by second dose anytime between 2–6 months later. Administer immediately upon reconstitution or store refrigerated and use within 6hrs.
<18yrs: not established.
Allergies to any previous Shingrix vaccination.
Review immunization history prior to administration. Have appropriate medical treatment and supervision available to manage allergic reactions. Pregnancy. Nursing mothers.
Immunosuppressants may reduce efficacy of Shingrix. Concomitant inactivated influenza vaccines: see full labeling.
Local reactions (eg, pain, redness, swelling), myalgia, fatigue, headache, shivering, fever, GI symptoms.
To report adverse events, contact VAERS at (800) 822-7967.
Single-dose vials—1, 10 (antigen + adjuvant components)